Skip to main content
. 2015 Oct;6(5):561–569. doi: 10.3978/j.issn.2078-6891.2015.037

Table 2. Ongoing clinical investigations targeting immune checkpoint blockade in gastric and esophageal cancer.

Study population Histology Number of samples PD-L1 positive (%) Outcome Reference
Esophageal Squamous 41 44 Worse outcomes (30)
Gastric Adenocarcinoma 102 42.2 Nodal mets, advanced stage (31)
Adenocarcinoma 111 63 Advanced stage, worse outcome (32)
Adenocarcinoma 243 43.6 Improved DFS, lower stage (49)

PD-L1, programmed death ligand 1; DFS, disease free survival.